Agomelatine Efficacy in Treating First-Episode Senile Depression-Journal of Psychiatry and Brain Science-CSCIED科技核心评价数据库-手机版

Agomelatine Efficacy in Treating First-Episode Senile Depression

Agomelatine Efficacy in Treating First-Episode Senile Depression

ES评分 0 浏览量：1027 下载量：0

DOI	10.20900/jpbs.20180002
刊名	Journal of Psychiatry and Brain Science JPBS
年，卷(期)	2018, 3(2)
作者	Juan.Niu*,Xiaoqin.Chen,Tiantian.Zhou,Yang.Yu,
作者单位	1 Psychological Clinic of the Affiliated Hospital of Qingdao University, Qingdao, Shandong 260071, China; 2 Qingdao Mental Health Center (Qingdao Seventh People’s Hospital), Qingdao, Shandong 266034, China; 3 Neurology Department of the Affiliated Hospital of Qingdao University, Qingdao, Shandong 266071, China
Abstract	Objective: To investigate agomelatine effects on first-episode senile depression patients.Methods: One hundred and sixteen elderly patients with first-episode senile depression were randomly and evenly divided into an observation group and a control group. The observation subjects were treated with agomelatine. The control subjects were treated with sertraline. The treatment effects, sleep improvement, and adverse reactions were compared. Results: After one week of treatment observation group The Hamilton Depression Rating Scale (HAMD) and Pittsburgh Sleep Quality Index (PSQI) scores after one week of treatment decreased significantly. After two weeks of treatment control group scores also decreased significantly (p < 0.01). Observation group HAMD scores were significantly lower than control group scores after weeks 1, 2, 4, and 8 (p < 0.05). Observation group PSQI scores were significantly lower than control group at the end of weeks 4 and 8 (p < 0.05). Observation group adverse incidence rate during administration was significantly lower than the control group (p < 0.05).Conclusion: Both agomelatine and sertraline are effective in treating first-episode depression elderly patients. Agomelatine has an earlier response, fewer adverse reactions and superior insomnia improvement.
KeyWord	First-episode senile depression; Agomelatine; Sertraline
基金项目
页码	-

参考文献
相关文献

1.Deng HM, Zhang H, Zhang Y, Wei L. Comprehensive Intervention combined with drug therapyin elderly patients with first-episode depression. J Int Psychiat. 2016; 43(3): 455-457.

2.Germain A, Kuper DJ. Circadian rhythm disturbances in depression. Hum Psychopharmacol. 2008; 23(7): 571-585.

3.De Berardis D, Brucchi M, Serroni N, Valchera A, Fornaro M, Mazza M, Martinotti G, Di Giannantonio M. Successful use of agomelatine in the treatment of major depression in a woman taking tamoxifen: a case report. Clin Neuropharmacol. 2014; 37(1): 31-33.

4.Zhang MY. Handbook of Rating Scales in Psychiatry. Hunan Science & Technology Press: Changsha, China, 1993. (in Chinese)

5.Imai H, Furukawa TA, Kasahara Y, Kimura Y, Fukutomi E, Chen WL, Tanaka M, Sakamoto R, Wada T, Fujisawa M, Okumiya K, Matsubayashi K. Ipsative imputation for a 15-item Geriatric Depression Scale in community-dwelling elderly people. Psychogeriat. 2014; 14(3): 182-187.

6.Heun R, Ahokas A, Boyer P, Giménez-Montesinos N, Pontes-Soares F, Olivier V; Agomelatine Study Group. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J Clin Psychiatry. 2013; 74: 587-594.

7.Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R. Comparative efficacy and acceptability of 12new-generationantidepressants: a multiple-treatmentsmeta-analysis. Lancet. 2009; 73: 746-758.

8.Quera-Salva MA, Hajak G, Philip P, Montplaisir J, Keufer-Le Gall S, Laredo J, Guilleminault C. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol. 2011; 26(5): 252-262.

9.Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet. 2011; 378(9791): 621-631.

引用本文

Juan.Niu*,Xiaoqin.Chen,Tiantian.Zhou,Yang.Yu. Agomelatine Efficacy in Treating First-Episode Senile Depression, Journal of Psychiatry and Brain Science. 2018; 3; (2). https://doi.org/10.20900/jpbs.20180002.

文献评论

相关学者

相关机构